N.A. Ognerubov1, D.N. Kushlinskiy2

1 G.R. Derzhavin Tambov State Medical University of the Ministry of Science and Higher Education of the Russian Federation (Tambov, Russia)

2 A.F. Tsyb MRRC – Branch of the Federal State Budgetary Institution «National Medical Research Center of Radiology» of the Ministry of Health of Russia (Moscow, Russia)

Every year, 295,414 cases of ovarian cancer and 184,799 deaths are registered in the world. The 5-year survival rate is less than 50%. About 75% of ovarian cancer is diagnosed at an advanced stage. The choice of treatment tactics for ovarian cancer is currently a difficult problem. It includes almost all existing special methods, including radiation therapy. Historically, radiation therapy has been used with success both for adjuvant purposes and for the treatment of locoregional relapses. The emergence of new effective drugs has unfairly displaced radiation therapy from the arena of therapeutic measures. Recently, new technologies of radiation therapy have made it possible to reconsider its possibilities in choosing a rational tactics for treating patients with ovarian cancer.

The aim of this work – is to analyze literature data on the results of the use of radiation therapy in an adjuvant mode after surgical treatment using various methods of irradiation in patients with ovarian cancer.

In a literature review, the authors cite in great detail the results of the use of radiation therapy in an adjuvant mode after surgical treatment of ovarian cancer using various radiation methods. A large section is devoted to the possibilities of radiation therapy in the development of local recurrences of ovarian cancer. For the treatment of the latter, the results of modern technologies are presented – IMRT, stereotactic radiation therapy, cyberknife. Undoubtedly, the merit of radiation therapy for the purposes of palliative care is obvious. The paper summarizes the authors' many years of experience in the use of radiotherapy with an adjuvant purpose after surgical treatment and in relapses of ovarian cancer.

These data indicate the need to revise the role of radiation therapy in ovarian cancer, which can become an alternative approach in the modern multimodal system of therapeutic measures.

Ognerubov N.A., Kushlinskiy D.N. Ovarian cancer: role and location of radiotherapy. Technologies of Living Systems. 2021. V. 18. №

4. Р. 5−20. DOI: https://doi.org/10.18127/j20700997-202104-01 (In Russian)

1. Voronina L.A., Ognerubov H.A., Evdokimova N.I., Sorokina A.Yu. Rol luchevogo komponenta v kompleksnom lechenii zlokachestvennykh opukholey yaichnikov. Novoye v onkologii: sbornik nauchnykh trudov. Voronezh. 1995. Vyp. 1. S. 137–139. (in Russian).
2. Granov A.M., Vinokurov V.L. Luchevaya terapiya v onkoginekologii i onkourologii. SPb. 2002. S. 115–141. (in Russian).
3. Ognerubov N.A., Voronina L.A., Klimova N.I. Opyt primeneniya luchevoy terapii v kompleksnom lechenii zlokachestvennykh opukholey yaichnikov. Rol luchevoy terapii v ginekologicheskoy onkologii: materialy nauchno-prakticheskoy konferentsii. Obninsk. 2002. S. 157– 159. (in Russian).
4. Ognerubov N.A., Voronina L.A., Klimova N.I. Effektivnost kompleksnogo lecheniya bolnykh zlokachestvennymi opukholyami yaichnikov. Novoye v onkologii: sbornik nauchnykh trudov. Voronezh. 1997. Vyp. 2. S. 189–192. (in Russian).
5. Ognerubov N.A., Voronina L.A., Subbotina I.A. Rol luchevoy terapii v klinicheskom lechenii bolnykh zlokachestvennymi opukholyami yaichnikov. Vysokiye tekhnologii v onkologii: materialy 5-go Vseross. syezda onkologov. Kazan. 2000. T. 2. S. 311–313. (in Russian).
6. Yurkova L.E., Chervyakov A.M., Shutko A.N., Chizhova N.A. Novaya tekhnologiya kombinirovannogo lecheniya rasprostranennogo raka yaichnikov s primeneniyem sistemnoy luchevoy terapii. Radiologiya – praktika. 2008. № 4. S. 19–23. (in Russian).
7. Albuquerque K., Patel M., Liotta M. et al. Long-term benefit of tumor volume- directed involved field radiation therapy in the management of recurrent ovarian cancer. Int. J. Gynecol. Cancer. 2016. V. 26. № 4. P. 655–660.
8. Allemani C., Matsuda T., Di Carlo V. et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018. V. 391. № 10125. P. 1023–1075.
9. Arians N., Kieser M., Benner L. et al. Adjuvant intensity modulated whole-abdominal radiation therapy for high-risk patients with ovarian cancer (International Federation of Gynecology and Obstetrics Stage III): first results of a prospective phase 2 study. Int. J. Rad. Oncol. 2017. V. 99. № 4. P. 912–920.
10. Barney B.M., Petersen I.A., Dowdy S.C. et al. Intraoperative electron beam radiotherapy (IOERT) in the management of recurrent ovarian malignancies. Int. J. Gynecol. Cancer. 2011. V. 21. № 7. P. 1225–1231.
11. Bellati F., Napoletano C., Gasparri M.L. et al. Current knowledge and open issues regarding bevacizumab in gynaecological neoplasms. Crit. Rev. Oncol. Hematol. 2012. V. 83. № 1. P. 35–46.
12. Biete A., Valduvieco I., Rovirosa A. et al. Whole abdominal radiotherapy in ovarian cancer. Rep. Pract. Oncol. Radiother. 2010. V. 15. № 2. P. 27–30.
13. Brown A.P., Jhingran A., Klopp A.H. et al. Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol. Oncol. 2013 V. 130. № 2. P. 300–305.
14. Chan J.K., Teoh D., Hu J.M. et al. Do clear cell ovarian carcinomas have poorer prognosis compared to other epithelial cell types? A study of 1411 clear cell ovarian cancers. Gynecol. Oncol. 2008. V. 109. № 3. P. 370–376.
15. Chundury A., Apicelli A., DeWees T. et al. Intensity modulated radiation therapy for recurrent ovarian cancer refractory to chemotherapy. Gynecol. Oncol. 2016. V. 141. № 1. P. 134–139.
16. De Geest K., Blessing J.A., Morris R.T. et al. Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinumand taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study. J. Clin. Oncol. 2010. V. 28. № 1. P. 149–153.
17. Dembo A.J. Epithelial ovarian cancer: the role of radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1992. V. 22. № 5. P. 835–845.
18. Dembo A.J. The role of radiotherapy in ovarian cancer. Bull. Cancer. 1982. V. 69. № 3. P. 275–283.
19. Dembo A., Bush R., Beale F. et al. A randomized clinical trial of moving strip versus open field whole abdominal irradiation in patients with in- vasive epithelial cancer of ovary. Gynecol. Oncol. 1984. V. 17. № 2. P. 256.
20. Deodato F., Macchia G., Grimaldi L. et al. Stereotactic radiotherapy in recurrent gynecological cancer: a case series. Oncol. Rep. 2009. V. 22. № 2. P. 415–419.
21. Dinniwell R., Lock M., Pintilie M. et al. Consolidative abdominopelvic radiotherapy after surgery and carboplatin/paclitaxel chemotherapy for epithelial ovarian cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005. V. 62. № 1. P. 104–110.
22. Eltabbakh G.H., Goodrich S. Update on the treatment of recurrent ovarian cancer. Womens Health (Lond.). 2006. V. 2. № 1. P. 127–139.
23. Formenti S.C., Rudqvist N.P., Golden E. et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat. Med. 2018.  V. 24. № 12. P. 1845–1851.
24. De Felice F., Marchetti C., Di Mino A., et al. Recurrent Ovarian Cancer: The Role of Radiation Therapy. Int. J. Gynecol. Cancer. 2017. V. 27. P. 690-695.
25. Fyles A.W., Thomas G.M., Pintilie M., Ackerman I., Levin W. A randomized study of two doses of abdominopelvic radiation therapy for patients with optimally debulked Stage I, II, and III ovarian cancer. Fules Clinical Trial. Int. J. Radiat. Oncol. Biol. Phys. 1998. V. 41. № 3. P. 543-549.
26. Gao Y., Liu Z., Chen X. et al. Intraoperative radiotherapy electron boost in advanced and recurrent epithelial ovarian carcinoma: a retrospective study. BMC Cancer. 2011. V. 11. № 439. P. 1–7.
27. Higginson D.S., Morris D.E., Jones E.L. et al. Stereotactic body radiotherapy (SBRT): technological innovation and application in gynecologic oncology. Gynecol. Oncol. 2011. V. 120. № 3. P. 404–412.
28. Hoskins P.J., Le N., Gilks B. et al. Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J. Clin. Oncol. 2012. V. 30. № 14. P. 1656–1662.
29. Iftode C., DʼAgostino G.R., Tozzi A. et al. Stereotactic body radiation therapy in oligometastatic ovarian cancer a promising therapeutic approach. Int. J. Gynecol. Cancer. 2018. V. 28. № 8. P. 1507–1513.
30. Iorio G.C., Martini S., Arcadipane F. et al. The role of radiotherapy in epithelial ovarian cancer: a literature overview. Medical Oncology. 2019. V. 36. № 7. P. 64.
31. Jones R.P., Stattner S., Sutton P. et al. Controversies in the oncosurgical management of liver limited stage IV colorectal cancer. Surg. Oncol. 2014. V. 23. № 2. P. 53–60.
32. Kajihara H., Yamada Y., Kanayama S. et al. Clear cell carcinoma of the ovary: potential pathogenic mechanisms (review). Oncol. Rep. 2010. V. 23. № 5. P. 1193–1203.
33. Kapp K.S., Kapp D.S., Poschauko J. et al. The prognostic significance of peritoneal seeding and size of postsurgical residual in patients with stage III epithelial ovarian cancer treated with surgery, chemotherapy, and high-dose radiotherapy. Gynecol. Oncol. 1999. V. 74. № 3. P. 400–407.
34. Kim H.S., Ahn J.H., Chung H.H. et al. Impact of intraoperative rupture of the ovarian capsule on prognosis in patients with early-stage epithelial ovarian cancer: a meta-analysis. Eur. J. Surg. Oncol. 2013. V. 39. № 3. P. 279–289.
35. Kobayashi H., Sumimoto K., Moniwa N. et al. Risk of developing ovarian cancer among women with ovarian endometrioma: а cohort study in Shizuoka, Japan. Int. J. Gynecol. Cancer. 2007. V. 17. № 1. P. 37–43.
36. Köbel M., Kalloger S.E., Huntsman D.G. et al. Cheryl Brown Ovarian Cancer Outcomes Unit of the British Columbia Cancer Agency, Vancouver BC. Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int. J. Gynecol. Pathol. 2010. V. 29. № 3. P. 203–211.
37. Köbel M., Kalloger S.E., Santos J.L. et al. Tumor type and substage predict survival in stage I and II ovarian carcinoma: insights and implications. Gynecol. Oncol. 2010. V. 116. № 1. P. 50–56.
38. Kumar A., Le N., Gilks C.B. et al. Survival benefit of adjuvant radiotherapy an analysis of low-stage invasive ovarian mucinous carcinomas. Int. J. Gynecol. Cancer. 2017. V. 27. № 9. P. 1819–1825.
39. Kumar A., Le N., Tinker A. et al. Early stage endometrioid ovarian carcinoma: population-based outcomes in British Columbia. Int. J. Gynecol. Cancer. 2014. V. 24. № 8. P. 1401–1405.
40. Kunos C.A., Brindle J., Waggoner S. et al. Phase II clinical trial of robotic stereotactic body radiosurgery for metastatic gynecologic malignancies. Front. Oncol. 2012. V. 2. № 181. P. 1–6.
41. Kunos C., Sill M., Buekers T. et al. Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase 1 study of the Gynecologic Oncology Group. Gynecol. Oncol. 2011. V. 120. № 2. P. 224–228.
42. Lazzari R., Ronchi S., Gandini S. et al. Stereotactic body radiation therapy for oligometastatic ovarian cancer: a step toward a drug holiday. Int. J. Radiation. Oncol. Biol. Phys. 2018. V. 101. № 3. P. 650–660.
43. Lee C.K., Simes R.J., Brown C. et al. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann. Oncol. 2013. V. 24. № 4. P. 937–943.
44. Lee S.W., Park S.M., Kim Y.M. et al. Radiation therapy is a treatment to be considered for recurrent epithelial ovarian cancer after chemotherapy. Tumori. 2011. V. 97. № 5. P. 590–595.
45. Linstadt D.E., Stern J.L., Quivey J.M. et al. Salvage whole-abdominal irradiation following chemotherapy failure in epithelial ovarian carcinoma. Gynecol. Oncol. 1990. V. 36. № 3. P. 327–330.
46. Loh J., Davis I.D., Martin J.M., Siva S. Extracranial oligometastatic renal cell carcinoma: current management and future directions. Future Oncol. 2014. V. 10. № 5. P. 761–774.
47. Macchia G., Lazzari R. A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 Study): a collaboration of MITO, AIRO GYN, and MaNGO Groups. Oncologist. 2019. pii: theoncologist. 2019-0309. doi: 10.1634/theoncologist.2019–0309
48. MacGibbon A., Bucci J., MacLeod C. et al. Whole abdominal radiotherapy following second-look laparotomy for ovarian carcinoma. Gynecol. Oncol. 1999. V. 75. № 1. P. 62–67.
49. Mayr N.A., Huang Z., Sohn J.W. et al. Emerging application of stereotactic body radiation therapy for gynecologic malignancies. Expert. Rev. Anticancer. Ther. 2011. V. 11. № 7. P. 1069–1075.
50. Mesko S.M., Sandler K.A., Cohen J. et al. Clinical outcomes for stereotactic ablative radiotherapy in oligometastatic and oligoprogressive gynecological malignancies. Int. J. Gyn. Cancer. 2017. V. 27. № 2. P. 403–408.
51. Mundt A.J., Lujan A.E., Rotmensch J. et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int. J. Radiat. Oncol. Biol. Phys. 2002. V. 52. № 5. P. 1330–1337.
52. Nagai Y., Inamine M., Hirakawa M. et al. Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol. Oncol. 2007. V. 107. № 3. P. 469–473.
53. National Comprehensive Cancer Network Guidelines. Available at: http:// www.nccn.org/professionals/physician_gls/pdf/ovarian.pdf. Accessed October 20, 2016.
54. Ognerubov N., Voronina L., Klimova N. The role of the radiation therapy in complex treatment of malignant tumors of ovaries. 8th International Congress, on Anti-Cancer Treatment. Paris. 1998. P. 75.
55. Patel S.C., Frandsen J., Bhatia S., Gaffney D. Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011. J. Gynecol. Oncol. 2016. V. 27. № 5. P. 1–9.
56. Patel S.C., Frandsen J., Bhatia S., Gaffney D. Impact on survival with adjuvant radiotherapy for clear cell, mucinous, and endometriod ovarian cancer: the SEER experience from 2004 to 2011. J. Gynecol. Oncol. 2016. V. 27. № 5. P. e45.
57. Pickel H., Lahousen M., Petru E. et al. Consolidation radiotherapy after carboplatin-based chemotherapy in radically operated advanced ovarian cancer. Gynecol. Oncol. 1999. V. 72. № 2. P. 215–219.
58. Reyes D.K., Pienta K.J. The biology and treatment of oligometastatic cancer. Oncotarget. 2015. V. 6. № 11. P. 8491–8524.
59. Rochet N., Kieser M., Sterzing F. et al. Phase II study evaluating consolidation whole abdominal intensity-modulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III–the OVAR-IMRT-02 Study. BMC Cancer. 2011. V. 11. № 41. P. 1–7.
60. Rodríguez-Ruiz M.E., Vanpouille-Box C., Melero I. et al. Immunological mechanisms responsible for radiation-induced abscopal effect. Trends Immunol. 2018. V. 39. № 8. P. 644–655.
61. Schiavone M.B., Herzog T.J., Lewin S.N. et al. Natural history and outcome of mucinous carcinoma of the ovary. Am. J. Obstet. Gynecol. 2011. V. 205. № 5. P. 480.e1–8.
62. Schray M.F., Martinez A., Howes A.E. et al. Advanced epithelial ovarian cancer: toxicity of whole abdominal irradiation after operation, combination chemotherapy, and reoperation. Gynecol. Oncol. 1986. V. 24. № 1. P. 68–80.
63. Serov S.F., Scully R.E., Sobin Z.H. Histologic typing of ovarian tumors. International Histologic Classification of Tumors 9th ed. Geneva. 1973. P. 17–18.
64. Shetty U.M., Shankar S., Engineer R. et al. Image-guided intensity-modulated whole abdominal radiation therapy in relapsed epithelial ovarian cancers: a feasibility study. J. Cancer Res. Ther. 2013. V. 9. № 1. P. 17–21.
65. Siegel R.L., Miller K.D., Jemal A. Cancer statistics 2017. CA Cancer J. Clin. 2017. V. 67. № 1. P. 7–30.
66. Smith J.P., Rutledge F.N., Delclos L. Postoperative treatment of early cancer of the ovary: a random trial between postoperative irradiation and chemotherapy. Natl. Cancer. Inst. Monogr. 1975. V. 42. P. 149–153.
67. Sorbe B. Swedish-Norgewian Ovarian Cancer Study Group. Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int. J. Gynecol. Cancer. 2003. V. 13. № 3. P. 278–286.
68. Swenerton K.D., Santos J.L., Gilks C.B. et al. Histiotype predicts the curative potential of radiotherapy: the example of ovarian cancers. Ann. Oncol. 2011. V. 22. № 2. P. 341–347.
69. US National Institutes of Health. US National Institutes of Health Clinical Trials Web site. Available at: https://clinicaltrials.gov
70. Yahara K., Ohguri T., Imada H. et al. Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy. J. Radiat. Res. 2013. V. 54. № 2. P. 322–329.
71. Yap O.W., Kapp D.S., Teng N.N., Husain A. Intraoperative radiation therapy in recurrent ovarian cancer. Int. J. Radiat. Oncol. Biol. Phys. 2005. V. 63. № 4. P. 1114–1121.
72. Mikhina Z.P. Luchevaya terapiya v kompleksnom lechenii epitelialnykh opukholey yaichnikov. Sovremennyye eksperimentalnyye i klinicheskiye podkhody k diagnostike i ratsionalnomu lecheniyu raka yaichnikov / Sb. statey. priurochennyy k Evropeyskoy shkole po onkologii. posvyashchennoy raku yaichnikov. M. 2001. S. 145–163. (in Russian).